Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study

BackgroundNon-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 (HER2) alterations poses a substantial treatment challenge. Current HER2-targeted therapies offer limited efficacy. Antibody-drug conjugates (ADCs) targeting HER2 have emerged as a promising therapeutic strate...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Meiling Zhang, Li Wang, Qian Wang, Jiu Yang, Wei Peng, Xiaoyou Li, Meiqi Shi, Kaihua Lu
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2024-11-01
Schriftenreihe:	Frontiers in Oncology
Schlagworte:	HER2 mutation HER2 amplification target non-small cell lung cancer RC48
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1441025/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!